# Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Source: https://onco.cc/trials/nct03742895/  
OnCo record `nct03742895` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Olaparib in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) is a phase 2 interventional study registered as NCT03742895 by Merck Sharp & Dohme LLC, with 329 participants enrolled, started 2018-12-12 and due to reach its primary completion in 2025-08-12. Interventions recorded: Olaparib. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03742895
- Phase: 2
- Setting: A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 329

## Sources

- ClinicalTrials.gov NCT03742895: https://clinicaltrials.gov/study/NCT03742895

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct03742895.json